Immuneel Therapeutics, a Bengaluru-based cell and gene therapy company, launched Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Hodgkin Lymphoma (B-NHL), a severe form of blood cancer. The treatment is priced at less than one-tenth of similar therapies available in Western countries.

Key Highlights:

• Innovative CAR-T Therapy:

Qartemi is using Chimeric Antigen Receptor (CAR-T) technology to target and destroy cancer cells by the patient's T-cells.
It is now the new hope for patients who have relapsed or refractory leukemia and lymphoma, wherein chemotherapy has not worked.

• Founders and Collaboration:

Immuneel was founded in 2018 by Kiran Mazumdar-Shaw, Indian-American oncologist and author Siddhartha Mukherjee, and venture capitalist Kush Parmar.
The company enjoys exclusive rights with Hospital Clinic de Barcelona to develop and commercialize a CD19 CAR-T cell therapy, ARI-0001, in India.

• Clinical Trials:

Qartemi clinical trials started in the year 2022. Clinical trials were conducted on patients at the Narayana Hospital in Bengaluru, Apollo Cancer Hospital in Chennai, and PGIMER in Chandigarh.

• Results:

Qartemi's safety profile and efficacy compared to the existing CAR-T cell therapies approved by the USFDA.

• Affordability:

Qartemi is available at a much more affordable price point compared to competitive therapies in developed countries, enabling the treatment to reach a greater number of patients in India.

Statements from Leaders or Officials:

• Kiran Mazumdar-Shaw, Co-Founder, Immuneel Therapeutics:

"Qartemi represents a major leap forward in making advanced cancer therapies accessible and affordable for patients in India. Our goal is to bring global standards of care to our country at an affordable cost."Qartemi is a launch that signifies India's increasing ability to deliver cutting-edge, affordable medical solutions. Immuneel Therapeutics, with its emphasis on innovation and accessibility, promises to revolutionize cancer care in the country, bringing hope to countless patients battling aggressive blood cancers.